Table 2. Estimated annual frequencies for the UK and European age-standardized rates per 100 000: based on HMRN sex- and age-specific rates data, 2004–2009.
|
Estimated cases: UK
|
European age-standardised rate (95% CI)
|
|||||
|---|---|---|---|---|---|---|
| Neoplasm (common abbreviation/synonym) | Total | Males | Females | Total | Males | Females |
| All diagnoses a | 29 017a | 16 264a | 12 752a | 40.8 (40.4–41.2)a | 51.1 (50.4–51.7)a | 32.7 (32.3–33.2)a |
| Total myeloid | 8549 | 4693 | 3855 | 11.7 (11.5–11.9) | 14.5 (14.1–14.8) | 9.6 (9.3–9.9) |
| Chronic myelogenous leukaemia (CML) | 533 | 313 | 220 | 0.8 (0.8–0.9) | 1.0 (0.9–1.2) | 0.7 (0.6–0.7) |
| Primary myelofibrosis | 232 | 155 | 77 | 0.3 (0.3–0.4) | 0.5 (0.4–0.6) | 0.2 (0.1–0.2) |
| Chronic myeloproliferative neoplasms (MPN) | 3138 | 1382 | 1756 | 4.3 (4.2–4.5) | 4.4 (4.2–4.6) | 4.4 (4.2–4.5) |
| Chronic myelomonocytic leukaemia (CMML) | 300 | 204 | 96 | 0.4 (0.4–0.5) | 0.6 (0.5–0.7) | 0.2 (0.2–0.3) |
| Myelodysplastic syndromes (MDS) | 2049 | 1382 | 667 | 2.5 (2.4–2.6) | 4.0 (3.8–4.2) | 1.5 (1.4–1.6) |
| Acute myeloid leukaemias (AML) | 2275 | 1245 | 1029 | 3.2 (3.1–3.4) | 4.0 (3.8–4.1) | 2.7 (2.5–2.8) |
| Total lymphoid a | 20 468a | 11 571a | 8897a | 29.1 (28.8–29.5)a | 36.6 (36.0–37.1)a | 23.1 (22.7–23.5)a |
| Precursor B-lymphoblastic leukaemia (B-ALL) | 540 | 279 | 261 | 1.0 (0.9–1.1) | 1.1 (0.9–1.2) | 1.0 (0.9–1.1) |
| Precursor T-lymphoblastic leukaemia (T-ALL) | 159 | 102 | 57 | 0.3 (0.2–0.3) | 0.4 (0.3–0.4) | 0.2 (0.1–0.3) |
| Monoclonal B-cell lymphocytosis (MBL)a | 1405a | 752a | 653a | 1.9 (1.8–2.0)a | 2.3 (2.2–2.5)a | 1.6 (1.5–1.7)a |
| Chronic lymphocytic leukaemia (CLL) | 3624 | 2259 | 1365 | 5.0 (4.8–5.1) | 7.0 (6.8–7.2) | 3.3 (3.1–3.4) |
| Marginal zone lymphomas (MZL) | 1682 | 959 | 723 | 2.3 (2.2–2.4) | 3.0 (2.8–3.1) | 1.8 (1.7–1.9) |
| Hairy-cell leukaemia (HCL) | 177 | 136 | 41 | 0.3 (0.2–0.3) | 0.4 (0.4–0.5) | 0.1 (0.1–0.2) |
| Monoclonal gammopathy of undetermined significance (MGUS)a | 3601a | 2059a | 1542a | 4.9 (4.8–5.0)a | 6.3 (6.0–6.5)a | 3.9 (3.7–4.1)a |
| Plasma cell myeloma (multiple myeloma) | 3553 | 2073 | 1480 | 4.7 (4.6–4.9) | 6.3 (6.1–6.6) | 3.5 (3.4–3.7) |
| Plasmacytoma | 318 | 211 | 107 | 0.5 (0.4–0.5) | 0.7 (0.6–0.8) | 0.3 (0.2–0.4) |
| Follicular lymphomas (FL) | 1754 | 821 | 933 | 2.7 (2.6–2.8) | 2.7 (2.5–2.8) | 2.7 (2.5–2.8) |
| Mantle-cell lymphoma | 454 | 295 | 159 | 0.6 (0.6–0.6) | 0.9 (0.8–0.1) | 0.4 (0.3–0.4) |
| Diffuse large B-cell lymphomas (DLBCL) | 4502 | 2353 | 2149 | 6.3 (6.1–6.4) | 7.3 (7.1–7.6) | 5.5 (5.3–5.7) |
| Burkitt lymphoma (BL) | 213 | 161 | 52 | 0.4 (0.3–0.4) | 0.6 (0.5–0.7) | 0.2 (0.1–0.2) |
| Lymphoproliferative disorders NOS (LPD) | 1026 | 557 | 469 | 1.3 (1.2–1.4) | 1.7 (1.6–1.8) | 1.0 (0.9–1.1) |
| T-cell leukaemia | 199 | 96 | 104 | 0.3 (0.2–0.3) | 0.3 (0.2–0.4) | 0.2 (0.2–0.3) |
| T-cell lymphoma | 601 | 351 | 249 | 0.9 (0.8–1.0) | 1.1 (1.0–1.3) | 0.7 (0.6–0.8) |
| Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) | 163 | 108 | 55 | 0.3 (0.2–0.3) | 0.4 (0.3–0.5) | 0.2 (0.1–0.2) |
| Classical Hodgkin lymphoma (CHL) | 1501 | 809 | 692 | 2.5 (2.4–2.6) | 2.8 (2.4–2.6) | 2.2 (2.1–2.4) |
Abbreviations: CI=confidence interval; NOS=not otherwise specified.
a
Data for monoclonal B-cell lymphocytosis (MBL) and monoclonal gammopathy of undetermined significance (MGUS) are excluded from the totals.